Retinoblastoma protein expression in ovarian epithelial neoplasms.

Abstract:

:Progress has been made in identifying the molecular changes that occur in ovarian carcinoma; still our understanding of these changes and their interactions remains incomplete. In the present study the authors examined the expression of retinoblastoma protein, a tumor suppressor protein, in a spectrum of ovarian epithelial tumors including cystadenomas, low-malignant-potential tumors, and carcinomas. A heterogeneous pattern of reactivity was observed in all of the cystadenomas, in all of the low-malignant-potential tumors, and in a majority (27/34) of the carcinomas. The remaining carcinomas showed either a complete absence of reactivity or a pattern of altered reactivity characterized by areas of tumor with intact reactivity adjacent to zones of tumor with a complete absence of reactivity. There was no significant association between grade or stage and absent/altered reactivity. We conclude that alterations of retinoblastoma protein expression are uncommon in ovarian carcinoma.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Niemann TH,Trgovac TL,McGaughy VR,Lewandowski GS,Copeland LJ

doi

10.1006/gyno.1998.5015

subject

Has Abstract

pub_date

1998-06-01 00:00:00

pages

214-9

issue

3

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(98)95015-6

journal_volume

69

pub_type

杂志文章
  • Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study.

    abstract:OBJECTIVE:To determine the antitumor activity and toxicity profile of gemcitabine as second-line chemotherapy in patients with recurrent or persistent uterine leiomyosarcoma (LMS). METHODS:Intravenous gemcitabine was administered over 30 min at a dose of 1000 mg/m(2) on days 1, 8, 15, with cycles repeated every 28 day...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1016/j.ygyno.2003.11.023

    authors: Look KY,Sandler A,Blessing JA,Lucci JA 3rd,Rose PG,Gynecologic Oncology Group (GOG) Study.

    更新日期:2004-02-01 00:00:00

  • Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB-IIA cervical cancer.

    abstract:OBJECTIVE:To determine the effectiveness of chemotherapy alone as postoperative adjuvant therapy for intermediate- and high-risk cervical cancer. METHODS:The study group comprised of 65 consecutive patients with stage IB or IIA squamous cell or adenosquamous cervical cancer who were initially treated with radical hyst...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2006.04.019

    authors: Takeshima N,Umayahara K,Fujiwara K,Hirai Y,Takizawa K,Hasumi K

    更新日期:2006-11-01 00:00:00

  • Characterization of 10 vulvar carcinoma cell lines by karyotyping, comparative genomic hybridization and flow cytometry.

    abstract:OBJECTIVE AND METHODS:Ten vulvar squamous cell carcinoma cell lines established at the University of Michigan (UM-SCV-1A, -1B, -2, -3, -4, -6, -7) and at the University of Turku (UT-SCV-1, -2, -3) were characterized by G-banding karyotyping, comparative genomic hybridization (CGH), and deoxyribonucleic acid (DNA) flow ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2003.12.033

    authors: Raitanen M,Worsham MJ,Lakkala T,Carey TE,Van Dyke DL,Grénman R,Klemi P,Rantanen V,Isola J,Grénman S

    更新日期:2004-04-01 00:00:00

  • PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.

    abstract:OBJECTIVE:Aberrant expression of HER2/neu and PIK3CA gene products secondary to amplification/mutations are common in high-grade-serous-endometrial (USC) and ovarian-cancers (HGSOC). Because scant information is currently available in the literature on the potential negative effect of PIK3CA mutations on the activity o...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2019.01.002

    authors: Bonazzoli E,Cocco E,Lopez S,Bellone S,Zammataro L,Bianchi A,Manzano A,Yadav G,Manara P,Perrone E,Haines K,Espinal M,Dugan K,Menderes G,Altwerger G,Han C,Zeybek B,Litkouhi B,Ratner E,Silasi DA,Huang GS,Azodi M,

    更新日期:2019-04-01 00:00:00

  • Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.

    abstract:OBJECTIVE:This study aims to identify favorable preoperative characteristics and examine the impact of secondary cytoreductive surgery on survival for patients with recurrent epithelial ovarian carcinoma. METHODS:Patients who underwent cytoreductive surgery for recurrent epithelial ovarian cancer were identified in ou...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2007.04.006

    authors: Tebes SJ,Sayer RA,Palmer JM,Tebes CC,Martino MA,Hoffman MS

    更新日期:2007-09-01 00:00:00

  • Three-dimensional coculture of endometrial cancer cells and fibroblasts in human placenta derived collagen sponges and expression matrix metalloproteinases in these cells.

    abstract:OBJECTIVE:Collagen gel constitutes a valuable tool for the study of cell-matrix interactions; however, it is sometimes difficult to use the gel, in which tumor and stromal cells are cocultured, for immunohistochemistry, because it is easily broken during the process of fixation and embedding in paraffin, especially aft...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/s0090-8258(03)00335-4

    authors: Tanaka R,Saito T,Ashihara K,Nishimura M,Mizumoto H,Kudo R

    更新日期:2003-08-01 00:00:00

  • Comparison of secondary and primary ovarian malignancies reveals differences in their pre- and perioperative characteristics.

    abstract:OBJECTIVE:Preoperative differentiation of primary and metastatic ovarian tumors is difficult. Young age of the patient, bilateralism and reduced multilocularity are cited characteristics of secondary ovarian malignancies. We sought to identity pre- and perioperative factors which may aid in differentiating metastatic o...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.09.046

    authors: Antila R,Jalkanen J,Heikinheimo O

    更新日期:2006-04-01 00:00:00

  • A phase II trial of bisantrene (CL216,942) in refractory epithelial ovarian cancer.

    abstract::Twenty-three evaluable patients with refractory epithelial ovarian cancer were treated with bisantrene (CL216,942). The drug was given as a single-dose injection every 3 weeks. One patient (4%) showed a partial response. The compound thus has limited activity against this malignancy. ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(86)90113-7

    authors: Kavanagh JJ,Gershenson DM,Saul PB,Copeland LJ

    更新日期:1986-01-01 00:00:00

  • Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.

    abstract:OBJECTIVE:Mucinous borderline ovarian tumor (mucinous-BOT) and invasive well-differentiated mucinous ovarian cancer (mucinous-OC) are often histopathologically misclassified. The objective of this study was to examine differences in clinico-pathological characteristics and outcomes of these two entities. METHODS:This ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2019.02.003

    authors: Matsuo K,Machida H,Mandelbaum RS,Grubbs BH,Roman LD,Sood AK,Gershenson DM

    更新日期:2019-05-01 00:00:00

  • A new score based on biomarker values to predict the prognosis of locally advanced cervical cancer.

    abstract:OBJECTIVE:To define a prognostic score based on pretreatment values of leucocyte, platelet and hemoglobin in locally advanced cervical cancer (LACC). MATERIAL AND METHODS:We conducted a prospective study of 238 patients for LACC with negative PET imaging in the para-aortic (PA) area and who were undergoing laparoscopi...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2020.08.002

    authors: Maulard A,Chargari C,Faron M,Alwohaibi A,Leary A,Pautier P,Genestie C,Morice P,Gouy S

    更新日期:2020-11-01 00:00:00

  • Symptoms, coping strategies, and timing of presentations in patients with newly diagnosed ovarian cancer.

    abstract:OBJECTIVE:The purpose was to explore whether health education on symptoms of ovarian cancer would aid in early detection, by examining the relationship between symptoms, coping strategies, and timing of presentation in patients with newly diagnosed ovarian cancer. METHODS:Eighty women were included. A questionnaire co...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/s0090-8258(03)00394-9

    authors: Chan YM,Ng TY,Lee PW,Ngan HY,Wong LC

    更新日期:2003-09-01 00:00:00

  • Survival probability in ovarian clear cell adenocarcinoma.

    abstract:OBJECTIVE:The aim of this study was to evaluate the 5-year survival probability (SP) of patients treated for ovarian clear cell adenocarcinoma (OCCA) at a single tertiary institution and to compare it to the 5-year SP of patients with other histologic subtypes of epithelial ovarian cancer. METHODS:Sixty-four patients ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1999.5445

    authors: Kennedy AW,Markman M,Biscotti CV,Emery JD,Rybicki LA

    更新日期:1999-07-01 00:00:00

  • Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III.

    abstract:OBJECTIVES:SGN-00101 (HspE7, Nventa, San Diego, CA) is a novel therapeutic vaccine consisting of a fusion protein containing an M. bovis BCG heat shock protein (Hsp65) covalently linked to the entire sequence of HPV 16 E7. This trial was designed to evaluate the efficacy and toxicities of HspE7 in women with CIN III. ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2007.04.038

    authors: Einstein MH,Kadish AS,Burk RD,Kim MY,Wadler S,Streicher H,Goldberg GL,Runowicz CD

    更新日期:2007-09-01 00:00:00

  • Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2.

    abstract:OBJECTIVES:Although many clinicians practice empiric dose reduction to prevent toxicity, it is unknown whether obese patients given chemotherapy dosed according to actual body weight (ABW) experience excess toxicity. At our institution, cancer patients receive chemotherapy dosed by ABW unless on a protocol capping dose...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2009.03.010

    authors: Schwartz J,Toste B,Dizon DS

    更新日期:2009-07-01 00:00:00

  • The prescription or proscription of exercise in endometrial cancer care.

    abstract:OBJECTIVE:To determine the proportion of endometrial cancer patients who can be safely prescribed community/home based unsupervised exercise. A better understanding of the physical dysfunction secondary to comorbidities among endometrial cancer patients would assist clinicians in delineating which patients to send to m...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2015.08.007

    authors: Zhang X,Haggerty AF,Brown JC,Giuntoli R 2nd,Lin L,Simpkins F,Dean LT,Ko E,Morgan MA,Schmitz KH

    更新日期:2015-10-01 00:00:00

  • Management of cryotherapy-ineligible women in a "screen-and-treat" cervical cancer prevention program targeting HIV-infected women in Zambia: lessons from the field.

    abstract:OBJECTIVE:We demonstrate the feasibility of implementing a referral and management system for cryotherapy-ineligible women in a "screen-and-treat" cervical cancer prevention program targeting HIV-infected women in Zambia. METHODS:We established criteria for patient referral, developed a training program for loop elect...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2008.04.031

    authors: Pfaendler KS,Mwanahamuntu MH,Sahasrabuddhe VV,Mudenda V,Stringer JS,Parham GP

    更新日期:2008-09-01 00:00:00

  • p16INK4A in routine practice as a marker of cervical epithelial neoplasia.

    abstract:OBJECTIVE:The aim of this study was to validate the role of p16(INK4a) immunocytochemistry as a marker of cervical epithelial neoplasia in cytology and biopsy samples. METHODS:During the period of 4 years a total of 501 immunocytochemistry stains in cytology and biopsy samples were performed. The cytology smears were ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2009.06.020

    authors: Kurshumliu F,Thorns C,Gashi-Luci L

    更新日期:2009-10-01 00:00:00

  • DNA ploidy of ovarian dysgerminomas: correlation with clinical outcome.

    abstract::Abnormal nuclear DNA content, as determined by flow cytometry, when combined with conventional prognostic variables such as tumor grade or stage at diagnosis, appears to identify patients who are at increased risk for recurrence of disease. The DNA content of ovarian dysgerminoma, a tumor that is homologous to testicu...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(92)90004-3

    authors: Palmquist MB,Webb MJ,Lieber MM,Gaffey TA,Nativ O

    更新日期:1992-01-01 00:00:00

  • The antitumor effect of metformin with and without carboplatin on primary endometrioid endometrial carcinoma in vivo.

    abstract:OBJECTIVES:New treatment options for advanced and recurrent endometrial carcinoma (EC) are necessary. Epidemiological studies showed that diabetic patients using metformin have reduced risks of endometrial cancer (EC) incidence. Moreover, pre- and clinical studies demonstrated an antitumor effect by metformin, with and...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2015.06.006

    authors: Schrauwen S,Coenegrachts L,Cattaneo A,Hermans E,Lambrechts D,Amant F

    更新日期:2015-08-01 00:00:00

  • Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience.

    abstract:BACKGROUND:One of the most active chemotherapy combinations in advanced or recurrent cervical cancer is cisplatin-paclitaxel. However, this palliative regimen is associated with significant toxicity. Carboplatin-paclitaxel is thus an attractive option. METHODS:Patients with advanced or recurrent carcinoma of the cervi...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.03.037

    authors: Tinker AV,Bhagat K,Swenerton KD,Hoskins PJ

    更新日期:2005-07-01 00:00:00

  • Endometrial adenocarcinoma arising in a secretory endometrium.

    abstract::Endometrial adenocarcinoma in young women below the age of 45 years and in a functioning endometrium is rare. We present the case of a 41-year-old woman, who without clinical risk factors, was found to have a focal well-differentiated endometrial adenocarcinoma in the background of a histologically secretory endometri...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1993.1122

    authors: Pai UL,Razi A,Selim MA,Petrelli M

    更新日期:1993-05-01 00:00:00

  • Analysis of disease recurrence and survival for women with uterine malignancies undergoing robotic surgery.

    abstract:OBJECTIVES:To evaluate recurrence-free survival (RFS) and overall survival (OS) for patients who underwent robotic-assisted laparoscopic hysterectomy (RALH) for uterine malignancies. METHODS:Medical records from 372 patients with uterine malignancies who underwent RALH from 3/06 to 3/09 at two institutions were review...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2012.11.005

    authors: Brudie LA,Backes FJ,Ahmad S,Zhu X,Finkler NJ,Bigsby GE 4th,Cohn DE,O'Malley D,Fowler JM,Holloway RW

    更新日期:2013-02-01 00:00:00

  • Clinical significance of enlarged cardiophrenic lymph nodes in advanced ovarian cancer: Implications for survival.

    abstract:OBJECTIVE:Advanced ovarian cancer (OC) commonly spreads to cardiophrenic lymph nodes (CPLNs), and is often visible on preoperative imaging. We investigated the prognostic significance of abnormal CPLNs in OC detected by preoperative CT scans using three different definitions. METHODS:Patients undergoing primary debulk...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2017.10.024

    authors: Mert I,Kumar A,Sheedy SP,Weaver AL,McGree ME,Kim B,Cliby WA

    更新日期:2018-01-01 00:00:00

  • Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer.

    abstract:OBJECTIVE:To determine if preoperative metabolic tumor volume (MTV) measured by integrated (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (FDG-PET/CT) imaging has prognostic value in patients with cervical cancer treated primarily with radical hysterectomy. METHODS:Patients with FIGO s...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2010.11.002

    authors: Chung HH,Kim JW,Han KH,Eo JS,Kang KW,Park NH,Song YS,Chung JK,Kang SB

    更新日期:2011-02-01 00:00:00

  • Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility.

    abstract:OBJECTIVE:To evaluate the optimal cytoreduction (OPT) rate, National Comprehensive Cancer Network (NCCN) treatment guideline compliance rate and patient outcomes for advanced stage epithelial ovarian cancer (EOC) patients at our low volume institution. METHODS:Following IRB approval, records of patients with Stage III...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2013.07.001

    authors: Phippen NT,Barnett JC,Lowery WJ,Miller CR,Leath CA 3rd

    更新日期:2013-10-01 00:00:00

  • Management of high-grade stage I adenocarcinoma of the endometrium: hysterectomy following low dose external beam pelvic irradiation.

    abstract::Sixty-eight patients with FIGO stage I, grade 2 or 3 adenocarcinoma of the endometrium were treated according to a protocol involving 10 Gy external pelvic irradiation, prompt hysterectomy with surgical staging, and postoperative therapy individualized according to surgical-pathologic findings. Five-year survival for ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(86)90222-2

    authors: Shimm DS,Wang CC,Fuller AF Jr,Nelson JH Jr,Nikrui N,Young RH,Scully RE

    更新日期:1986-02-01 00:00:00

  • Laparoscopy-assisted vaginal pelvic exenteration.

    abstract:OBJECTIVE:The aim of this study was to evaluate the feasibility, morbidity and survival outcome of laparoscopy-assisted vaginal pelvic exenteration. METHODS:Since 2000, we have performed 5 cases of en-bloc pelvic exenteration combining a vaginal or perineal approach and laparoscopic approach. All patients had received...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.09.027

    authors: Ferron G,Querleu D,Martel P,Letourneur B,Soulié M

    更新日期:2006-03-01 00:00:00

  • Management of the adnexal mass.

    abstract::The methods for preoperative diagnosis and evaluation of the woman with a suspected ovarian neoplasm have evolved significantly with little or no impact on the surgical treatment, which remains removal of the abnormal ovary. Although most adnexal masses are benign, the primary goal of the diagnostic evaluation is the ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1006/gyno.1994.1340

    authors: Curtin JP

    更新日期:1994-12-01 00:00:00

  • Role of microRNAs in drug-resistant ovarian cancer cells.

    abstract:OBJECTIVES:Chemotherapy is the preferred therapeutic approach for the therapy of advanced ovarian cancer, but a successful long-term treatment is prevented by the development of drug resistance. Recent works have underlined the involvement of non-coding RNAs, microRNAs (miRNAs) in cancer development, with several conje...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2008.08.017

    authors: Sorrentino A,Liu CG,Addario A,Peschle C,Scambia G,Ferlini C

    更新日期:2008-12-01 00:00:00

  • Resveratrol inhibits ovarian cancer cell adhesion to peritoneal mesothelium in vitro by modulating the production of α5β1 integrins and hyaluronic acid.

    abstract:OBJECTIVE:Resveratrol (Res) is known to inhibit adhesion of numerous malignancies though its effect on an adherence of ovarian cancer cells to peritoneal mesothelium remains undefined. METHODS:To address this issue, ovarian cancer cells (A2780, OVCAR-3, SKOV-3) were subjected to Res (10, 50, 100 μM), and then their ad...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2014.06.022

    authors: Mikuła-Pietrasik J,Sosińska P,Książek K

    更新日期:2014-09-01 00:00:00